KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Asset Writedowns and Impairment (2018 - 2025)

Historic Asset Writedowns and Impairment for Novavax (NVAX) over the last 8 years, with Q3 2025 value amounting to $97.0 million.

  • Novavax's Asset Writedowns and Impairment changed N/A to $97.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.1 million, marking a year-over-year increase of 565721.99%. This contributed to the annual value of $4.1 million for FY2024, which is 5901.2% down from last year.
  • Latest data reveals that Novavax reported Asset Writedowns and Impairment of $97.0 million as of Q3 2025.
  • In the past 5 years, Novavax's Asset Writedowns and Impairment ranged from a high of $155.7 million in Q2 2022 and a low of -$1.3 million during Q4 2024
  • In the last 4 years, Novavax's Asset Writedowns and Impairment had a median value of $5.9 million in 2023 and averaged $43.9 million.
  • Data for Novavax's Asset Writedowns and Impairment shows a peak YoY increase of 9352.54% (in 2023) and a maximum YoY decrease of 9352.54% (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows Novavax's Asset Writedowns and Impairment stood at $155.7 million in 2022, then plummeted by 93.53% to $10.1 million in 2023, then tumbled by 112.89% to -$1.3 million in 2024, then skyrocketed by 7570.21% to $97.0 million in 2025.
  • Its last three reported values are $97.0 million in Q3 2025, $349000.0 for Q2 2025, and -$1.3 million during Q4 2024.